Metraipolis › archive › dc_647512ce3dea
'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch… — Europe PMC PMID:42136197
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42136197
- DOI
- 10.1093/jac/dkag172
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T22:08:19.123Z
- SHA-256 of the archived text
271d8c117828e3c98860d66c9db7fe7e7ed9ff76271703d1a3c0887f50ec9260- Stable URL of this page
https://metraipolis.com/documento/dc_647512ce3dea
How to cite
'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch… — Europe PMC PMID:42136197 — Europe PMC (en), https://europepmc.org/article/MED/42136197 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_647512ce3dea (Metraipolis archive dc_647512ce3dea, sha256 271d8c117828e3c98860d66c9db7fe7e7ed9ff76271703d1a3c0887f50ec9260)
BibTeX
@misc{dc647512ce3dea,
title = {'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch… — Europe PMC PMID:42136197},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42136197},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_647512ce3dea; sha256 271d8c117828e3c98860d66c9db7fe7e7ed9ff76271703d1a3c0887f50ec9260},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42136197. Agents can read the archived copy with the MCP tool read_document.